The exit market is reopening. After three years in which the path to public-market liquidity was effectively closed for most venture-backed companies, IPOs are pricing again, acquisition activity is returning, and the trade press has shifted from "the window is shut" to "the window is open." For private-company shareholders who have been waiting years for a liquidity event, that is real news — and it is worth understanding precisely, because the headline does more work than the underlying reality supports.
A reopening exit market is a market-wide signal: when exits return, secondary discounts narrow, buyers re-engage, and every private shareholder faces the same hold-versus-sell question at roughly the same time. But the reopening is narrow, the public market it opens onto is still shrinking, and the benefit reaches the top tier of private companies well before it reaches the long tail. This piece walks through what is actually reopening, the structural catch underneath it, why a reopening doesn't reach most shareholders evenly, how it changes secondary pricing, and how it should — and shouldn't — reframe the decision to sell now or hold.
This is not tax advice. Consult a qualified tax professional before you sell private company shares.
Key concept
A reopening exit market is a real liquidity signal, but it is not a uniform one. Discounts narrow first and most for the roughly two dozen companies with credible, near-term IPO paths and established secondary markets. For most venture-backed companies, a reopening changes the headlines before it changes the offer a shareholder can actually get. The diligence question isn't "is the window open?" — it's "is it open for my company, and has it changed the specific quote in front of me?"
What's Actually Reopening in the Exit Market?
The 2026 data is genuinely better than the prior three years, and it's worth stating the good news plainly before complicating it.
Through March 31, 2026, 22 traditional IPOs raised over $9.4 billion — the strongest first quarter in five years, against 15 IPOs raising roughly $7.9 billion in the same period of 2025, per PwC's US Capital Markets Watch. Offerings priced successfully across industrials, healthcare, technology, and consumer sectors, and 2026 IPOs have on average traded roughly in line with — and slightly better than — the broader market. On the exit side more broadly, global exit value was up more than 80% year-over-year through the first nine months of 2025. The machinery that had seized up is moving again.
The pipeline reinforces the narrative. A short list of very large private companies — names like SpaceX, OpenAI, and Anthropic are the ones most often cited in public reporting — are widely expected to consider public offerings, and any one of them would be among the largest listings in history. When the headline IPO is measured in hundreds of billions of dollars, the reopening feels total. That feeling is the thing to examine.
The Catch: The Public Market Itself Is Still Shrinking
A reopening window opens onto a shrinking room. The reopening is happening inside a public market that has been contracting for three decades, and that long-run trend is the context the cyclical good news sits inside.
The number of US-listed public companies peaked at 8,090 in 1996 and has fallen to roughly 3,700 to 4,500 today, depending on the count — a decline of more than 40% even as the US economy has more than tripled in size, per Harvard Law School Forum on Corporate Governance analysis and CNN's reporting on the same data. The bar to go public has also risen: companies that did list in 2025 took a median of more than 11 years to get there — the longest in a decade, per PwC. Rising listing costs, the abundance of private capital, and a higher revenue threshold for a credible IPO have all pushed the same direction.
The implication for a shareholder is structural, not seasonal. The IPO is no longer the default endpoint of a venture-backed company's life — it is the exception, reserved for a shrinking set of the largest names. A reopening window is good news for the companies that can credibly walk through it. It does not change the fact that thousands of mid-stage companies with real revenue have no realistic public exit on any near horizon. For shareholders at those companies, we've written separately about what happens to your equity if your company never IPOs — and a reopening exit market does little to change that base case.
Why a Reopening Doesn't Reach Most Shareholders
Even within the private market, liquidity is not evenly distributed — and a reopening flows along the channels that already exist.
Secondary trading is heavily concentrated. In Q4 2025, the top 20 companies accounted for roughly 86% of global secondary trading value, with the top five alone representing more than half, per Hiive platform data. We unpack this in detail in why 86% of venture secondary volume concentrates in just 20 companies. These are the same names that dominate the IPO pipeline: companies with enormous valuations, abundant buyers, and established secondary markets where deals clear reliably.
A reopening lifts that concentrated top tier first. When an IPO becomes credible for one of these companies, its secondary discount compresses, its buyer pool deepens, and the path to liquidity shortens — sometimes well ahead of the listing itself. For a shareholder at a company outside that set, the aggregate market can be reopening while their own situation is unchanged. The reopening is real; it just hasn't arrived at their cap table.
⚠️ "The exit market is reopening" and "I can now sell my shares at a better price" are two different statements. The first is about the market in aggregate. The second is about your specific company, your specific share class, and the specific buyers willing to underwrite it. A reopening makes the first more likely without guaranteeing the second.
This is the same split we mapped in The 2026 Private Market Bifurcation: a top tier moving on its own logic, and a broad middle that the headline narrative — whether the headline is "macro headwinds" or "the window is reopening" — describes poorly.
How a Reopening Changes Secondary Pricing
When exits return, the mechanics of secondary pricing move in a predictable direction — within limits.
Discounts narrow where the exit is credible. A secondary buyer prices private shares at a discount to the last priced round partly to compensate for illiquidity and for the uncertainty of when — and whether — a liquidity event will arrive. When a credible IPO shortens the expected holding period and reduces that uncertainty, buyers will pay more relative to the last round. That's why the secondary discount tends to compress as a real exit comes into view.
The buyer pool deepens. A reopening that returns capital to funds and signals that exits are achievable brings buyers back to the table who had stepped away. More bidders, at the margin, means better clearing prices — again, concentrated where the exit story is most believable.
But compression is concentrated, and "untradeable" is not the same as "discounted." For the broad market, discounts narrow later and less. And there's a floor case worth naming: a company with no credible buyers isn't trading at a discount — it's effectively untradeable until a buyer appears at any price. A reopening can pull some companies from "untradeable" toward "tradeable at a discount," which is meaningful. It does not make every private company liquid.
The Hold-Versus-Sell Decision, Reframed
A reopening exit market changes the inputs to the hold-versus-sell question. It does not change the question, and it does not answer it. Whether to sell now or hold is a personal decision that depends on circumstances no market signal can resolve — and the considerations below are the same ones that apply in any environment, simply reweighted by the reopening.
Concentration of your own net worth. If a single private company represents most of your wealth, the case for converting some portion to cash is about your exposure, not the market's direction. A reopening that improves pricing can make a partial sale less costly; it doesn't change the underlying concentration question.
The tax timing of an option exercise. For employees holding options rather than shares, exercising can trigger a tax bill long before any liquidity exists to pay it — and that timing problem is independent of whether the window is open. Any decision that involves exercising to sell has tax consequences that vary widely by equity type, holding period, and state. We cover the landscape in tax considerations in a secondary sale, but this is exactly where a qualified professional earns their fee.
ROFR and transfer restrictions. A reopening does nothing to remove the company's right of first refusal or the transfer restrictions in your equity agreements. Those mechanics govern whether and how you can sell at all, regardless of how warm the market feels.
The gap between a discount now and an exit you don't control. The honest framing of the decision is a comparison: a known price available today, at some discount, versus an uncertain future price at a liquidity event whose timing you do not control. A reopening narrows that gap for companies with credible near-term exits. For everyone else, the gap is roughly what it was — and "the window is reopening" is not, by itself, evidence that it has narrowed for you.
For a fuller walk through the trade-offs on the shareholder side, see the factors that go into deciding whether to sell startup shares and the broader menu of startup equity liquidity options.
What to Watch From Here
The useful posture is to treat the reopening as a question about your own company rather than a verdict on the market. A few signals tell you whether the aggregate good news has reached you: whether your company has a credible, public exit path on a near horizon; whether secondary quotes for your share class have actually moved; whether the buyer pool for your specific company has deepened; and whether the discount you'd be quoted today has compressed relative to six months ago.
If those signals have moved, the reopening is real for you, and the hold-versus-sell math has genuinely shifted. If they haven't, the headline is describing a market you're adjacent to rather than in — and the decision rests on the same fundamentals it always did: your concentration, your tax situation, your time horizon, and the price actually in front of you. A reopening exit market is good news. Whether it's your news is a separate, and more useful, question to answer.
Weighing a sale in a reopening market?
We're happy to share our perspective.
If you're a shareholder trying to read whether the reopening has reached your company — or an allocator sizing the same signal — we'd encourage you to reach out. We're always happy to share our thinking, no commitment required.
Get in touch →contact@earlyasset.com · We typically respond within one business day
Earlyasset, Inc. does not provide investment advice and is not a registered investment adviser. Pricing estimates are algorithmic and do not constitute an offer to buy or sell securities. All transactions respect the company's right of first refusal (ROFR) and any transfer restrictions in your equity agreements. Direct liquidity is provided by Earlyasset Capital, LLC, a separate entity from Earlyasset, Inc.
Source note: IPO activity figures (22 traditional IPOs raising over $9.4 billion through March 31, 2026; the 2025 comparison; and the median time-to-IPO exceeding 11 years) are sourced from PwC's US Capital Markets Watch and related 2026 reporting, current as of Q1 2026. The long-run decline in US-listed public companies (a 1996 peak of 8,090, falling below 4,500 today) is sourced from the Harvard Law School Forum on Corporate Governance and CNN's reporting on Center for Research in Security Prices data. Secondary market concentration figures (top 20 companies at ~86% of Q4 2025 global secondary trading value) reflect Hiive platform data as cited in prior Earlyasset Research analysis. Company names referenced as IPO candidates (SpaceX, OpenAI, Anthropic) reflect publicly reported expectations as of mid-2026; Earlyasset is not affiliated with any of these companies and has no non-public information about their plans. Figures reflect a snapshot at the time of writing and will change as markets move.
Tax disclaimer: This article is general educational content only and does not constitute tax, legal, or financial advice. Tax treatment of secondary transactions varies significantly based on equity type, holding period, state of residence, individual circumstances, and other factors. Consult a qualified CPA, tax attorney, or financial advisor before making any transaction decision. Earlyasset, Inc. is not a tax advisor and does not provide tax guidance.
Not investment advice. This article is general analytical content. It is not a recommendation to buy, sell, or hold any specific security, nor a recommendation about whether any shareholder should seek liquidity now or wait. Shareholders considering a sale, and allocators considering an investment, should consult their own legal, tax, and financial advisors before acting.